Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492780 | 0.83 | LMNA (0.58) | RAB9ALMNAKMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL2974364 | 0.83 | LMNA (0.58) | RAB9ALMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL30416070 | 0.78 | EPHX2 (0.83) | LMNASMN1; SMN2EPHX2CD274MAPT | |
| SCHEMBL11005634 | 0.78 | KCNMA1 (0.66) | RAB9AKMT2AMAPTMEN1STAT3 | |
| SCHEMBL2964824 | 0.76 | LMNA (0.62) | LMNAKMT2ASMN1; SMN2EPHX2CD274 | |
| SCHEMBL15717137 | 0.75 | RAB9A (0.64) | RAB9ALMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL29689487 | 0.75 | RAB9A (0.64) | RAB9ALMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL5247238 | 0.75 | RAB9A (0.70) | RAB9ALMNAKMT2ASMN1; SMN2MAPT | |
| SCHEMBL13219988 | 0.74 | LMNA (0.57) | LMNAKMT2ASMN1; SMN2EPHX2CD274 | |
| SCHEMBL30417071 | 0.73 | ALDH1A1 (0.76) | LMNAKMT2ASMN1; SMN2EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | RAB9A 3546/4885LMNA 1675/4885KMT2A 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.